临近 #ESMO26，热点成果层出不穷。
不甘示弱于 AZUR-1、CheckMate 8HW 或其他令人惊叹的 IO 突破，Chalabi 发布了 NICHE-2 的长期随访结果。
一言以蔽之？完美。
111 例局部晚期 dMMR 结肠癌患者。仅接受 6 周新辅助纳武利尤单抗/伊匹单抗治疗后行手术。
零复发。5 年总生存率 100%。
请记住，这些并非全是低风险肿瘤。许多属于高风险 III 期疾病。
我们仅用几周免疫治疗就治愈了患者。
现在，能否完全避免手术？
治疗胃肠癌的时代真好。
@TheGutOncLab @OncoAlert @Onco_Nexus
https://www.sciencedirect.com/science/article/pii/S0140673626016028
3098 浏览 · 57 赞 · 22 转发 · 3 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org- A.n.n.@fireflyann
@GIMedOnc I saw Dr @MyriamChalabi slides in 2018.. in Dutch... but could see the word of crc was changing!!!
- Nicholas Hornstein@GIMedOnc
@agrothey Don’t get me started on ATOMIC…
- Axel Grothey@agrothey
@GIMedOnc And move over, ATOMIC!
来源：Nicholas Hornstein · x.com